

Thomas M Pilgrim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1783094/publications.pdf>

Version: 2024-02-01

307
papers

14,038
citations

22099

59
h-index

26548

107
g-index

327
all docs

327
docs citations

327
times ranked

12319
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgical versus transcatheter repair for secondary mitral regurgitation: A propensity score-matched cohorts comparison. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 2037-2046.e4.	0.4	15
2	Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. <i>Cardiovascular Revascularization Medicine</i> , 2022, 34, 3-10.	0.3	5
3	Systemic Corticosteroid Exposure and Atrioventricular Conductance Delays After Transcatheter Aortic Valve Implantation. <i>Cardiovascular Revascularization Medicine</i> , 2022, 37, 1-6.	0.3	2
4	Clinical impact of left atrial appendage filling defects in patients undergoing transcatheter aortic valve implantation. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1354-1364.	0.5	2
5	Anatomical and Technical Predictors of Three-Dimensional Mitral Valve Area Reduction After Transcatheter Edge-To-Edge Repair. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 96-104.	1.2	13
6	Predictors of Prosthetic Valve Regurgitation After Transcatheter Aortic Valve Implantation With ACURATE neo in the SCOPE I Trial. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 367-369.	2.3	6
7	Clinical outcomes following transcatheter aortic valve implantation in patients with porcelain aorta. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 215-221.	0.7	4
8	Prevalence of latent structural heart disease in Nepali schoolchildren. <i>Cardiology in the Young</i> , 2022, 32, 1151-1153.	0.4	0
9	Sinus of Valsalva Dimension and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>American Heart Journal</i> , 2022, 244, 94-106.	1.2	8
10	Validation of the VARC-3 Technical Success Definition in Patients Undergoing TAVR. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 353-364.	1.1	11
11	Electrosurgical Laceration and Stabilization of MitraClip Followed by Valve Implantation for Iatrogenic Mitral Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 110-112.	1.1	4
12	Reproducibility of 4D cardiac computed tomography feature tracking myocardial strain and comparison against speckle-tracking echocardiography in patients with severe aortic stenosis. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 309-318.	0.7	11
13	Acute coronary syndromes in young patients: Phenotypes, causes and clinical outcomes following percutaneous coronary interventions.. <i>International Journal of Cardiology</i> , 2022, 350, 1-8.	0.8	5
14	Frequency and Outcomes of Periprocedural MI in Patients With Chronic Coronary Syndromes Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2022, 79, 513-526.	1.2	24
15	Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification. <i>PLoS ONE</i> , 2022, 17, e0263180.	1.1	3
16	Cardiovascular outcomes in patients with left atrial enlargement undergoing transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	0.7	1
17	Impact of First-Phase Ejection Fraction on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Cardiovascular Revascularization Medicine</i> , 2022, 42, 55-61.	0.3	2
18	Transcatheter aortic valve implantation in patients with rheumatic aortic stenosis. <i>Heart</i> , 2022, 108, 1225-1233.	1.2	3

#	ARTICLE	IF	CITATIONS
19	Diagnostic performance of quantitative coronary artery disease assessment using computed tomography in patients with aortic stenosis undergoing transcatheter aortic-valve implantation. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 178.	0.7	6
20	Five-year outcomes of mild paravalvular regurgitation after transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2022, 18, 33-42.	1.4	42
21	Long-term outcomes of new-onset conduction abnormalities following transcatheter aortic valve implantation. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 214-224.	0.7	3
22	Reply: Correlation of aortic root dimensions in patients undergoing transcatheter aortic valve implantation. <i>American Heart Journal</i> , 2022, 248, 166-168.	1.2	0
23	Assessment of New Onset Arrhythmias After Transcatheter Aortic Valve Implantation Using an Implantable Cardiac Monitor. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	2
24	Magmaris Resorbable Magnesium Scaffold Versus Conventional Drug-Eluting Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity-Score-Matching Comparison. <i>Cardiovascular Revascularization Medicine</i> , 2022, 43, 28-35.	0.3	6
25	Transcatheter aortic valve-in-valve implantation to treat aortic Para-valvular regurgitation after TAVI. <i>International Journal of Cardiology</i> , 2022, , .	0.8	1
26	Penicillin reduces latent rheumatic-heart-disease progression. <i>Journal of Pediatrics</i> , 2022, 245, 246-249.	0.9	0
27	Risk and Timing of Noncardiac Surgery After Transcatheter Aortic Valve Implantation. <i>JAMA Network Open</i> , 2022, 5, e2220689.	2.8	4
28	Impact of membranous septum length on pacemaker need with different transcatheter aortic valve replacement systems: The INTERSECT registry. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 524-530.	0.7	17
29	Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1543-1554.	1.1	12
30	Clinical impact of mitral calcium volume in patients undergoing transcatheter aortic valve implantation. <i>Journal of Cardiovascular Computed Tomography</i> , 2021, 15, 356-365.	0.7	20
31	Impact of Proportionality of Secondary Mitral Regurgitation on Outcome After Transcatheter Mitral Valve Repair. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 715-725.	2.3	42
32	Meta-Analysis of Bioprosthetic Valve Thrombosis After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 138, 92-99.	0.7	27
33	Synergistic Effect of 2 Transcatheter Tricuspid Valve Treatment Modalities. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, e5-e7.	1.1	0
34	Discharge Location and Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 140, 95-102.	0.7	2
35	Mapping routine measles vaccination in low- and middle-income countries. <i>Nature</i> , 2021, 589, 415-419.	13.7	71
36	Deferred versus Expedited Aortic Valve Replacement in Patients with Symptomatic Severe Aortic Stenosis During the SARS-CoV-2 Pandemic (AS DEFER): A Research Letter. <i>Global Heart</i> , 2021, 16, 32.	0.9	3

#	ARTICLE	IF	CITATIONS
37	Unplanned Percutaneous Coronary Revascularization After TAVR. JACC: Cardiovascular Interventions, 2021, 14, 198-207.	1.1	30
38	Safety and Efficacy of Transcatheter Aortic Valve Replacement With Continuation of Vitamin K Antagonists or Direct Oral Anticoagulants. JACC: Cardiovascular Interventions, 2021, 14, 135-144.	1.1	19
39	Transcatheter Aortic Valve Replacement With the LOTUS Edge System. JACC: Cardiovascular Interventions, 2021, 14, 172-181.	1.1	6
40	True-severe stenosis in paradoxical low-flow low-gradient aortic stenosis: outcomes after transcatheter aortic valve replacement. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 366-377.	1.8	4
41	Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 98, E213-E221.	0.7	3
42	Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI. JACC: Cardiovascular Interventions, 2021, 14, 639-648.	1.1	33
43	One-Year Outcomes of a Randomized Trial Comparing a Self-Expanding With a Balloon-Expandable Transcatheter Aortic Valve. Circulation, 2021, 143, 1267-1269.	1.6	8
44	Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese Schoolchildren. JAMA Cardiology, 2021, 6, 420.	3.0	22
45	Mid-term outcome of children with latent rheumatic heart disease in eastern Nepal. Open Heart, 2021, 8, e001605.	0.9	3
46	Staging cardiac damage associated with aortic stenosis in patients undergoing transcatheter aortic valve implantation. IJC Heart and Vasculature, 2021, 33, 100768.	0.6	8
47	Heart valve sizing and clinical outcomes in patients undergoing transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2021, 98, E768-E779.	0.7	7
48	Anaesthesia for minimally invasive cardiac procedures in the catheterization lab. Current Opinion in Anaesthesiology, 2021, 34, 437-442.	0.9	1
49	ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2187-2199.	1.2	35
50	Validation of the 2019 Expert Consensus Algorithm for the Management of Conduction Disturbances After TAVR. JACC: Cardiovascular Interventions, 2021, 14, 981-991.	1.1	14
51	Percutaneous mechanical circulatory support from the collaborative multicenter Mechanical Unusual Support in <sc>TAVI</sc> (<sc>MUST</sc>) Registry. Catheterization and Cardiovascular Interventions, 2021, 98, E862-E869.	0.7	9
52	Bioprosthetic valve fracture: Predictors of outcome and <sc>followâ€p</sc>. Results from a multicenter study. Catheterization and Cardiovascular Interventions, 2021, 98, 756-764.	0.7	6
53	Age-Related Outcomes After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 952-960.	1.1	28
54	Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials. American Heart Journal, 2021, 235, 140-148.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2263-2273.	1.2	19
56	Refined staging classification of cardiac damage associated with aortic stenosis and outcomes after transcatheter aortic valve implantation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 532-541.	1.8	22
57	The impact of obesity on left ventricular hypertrophy and diastolic dysfunction in children and adolescents. <i>Scientific Reports</i> , 2021, 11, 13022.	1.6	14
58	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , 2021, 10, e021965.	1.6	23
59	Feasibility of Coronary Access in Patients With Acute Coronary Syndrome and Previous TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1578-1590.	1.1	18
60	Effect of Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition vs Placebo in Patients With Anterior Myocardial Infarction. <i>JAMA Cardiology</i> , 2021, 6, 1171.	3.0	7
61	Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. <i>International Journal of Cardiology</i> , 2021, 334, 37-41.	0.8	2
62	Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. <i>New England Journal of Medicine</i> , 2021, 385, 2150-2160.	13.9	144
63	Incidence, Causes, and Outcomes Associated With Urgent Implantation of a Supplementary Valve During Transcatheter Aortic Valve Replacement. <i>JAMA Cardiology</i> , 2021, 6, 936.	3.0	7
64	Integrative echocardiographic assessment of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1404-1412.	0.7	1
65	Permanent pacemaker implantation late after transcatheter aortic valve implantation. <i>Heart Rhythm</i> , 2021, 18, 2033-2039.	0.3	11
66	Incidence and Outcomes of Infective Endocarditis After Transcatheter or Surgical Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2021, 10, e020368.	1.6	14
67	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2021, 398, 870-905.	6.3	229
68	Comparison of Transvalvular Aortic Mean Gradients Obtained by Intraprocedural Echocardiography and Invasive Measurement in Balloon and Self-Expanding Transcatheter Valves. <i>Journal of the American Heart Association</i> , 2021, 10, e021014.	1.6	22
69	Potential Candidates for Transcatheter Tricuspid Valve Intervention After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2246-2256.	1.1	20
70	Deep learning-based prediction of early cerebrovascular events after transcatheter aortic valve replacement. <i>Scientific Reports</i> , 2021, 11, 18754.	1.6	8
71	Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1-14.	1.2	64
72	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. <i>EuroIntervention</i> , 2021, 17, e898-e909.	1.4	45

#	ARTICLE	IF	CITATIONS
73	Transcatheter paravalvular leak closure: catch me if you can. <i>EuroIntervention</i> , 2021, 17, 699-700.	1.4	2
74	Differential Effects of Newer-Generation Ultrathin-Strut Versus Thicker-Strut Drug-Eluting Stents in Chronic and Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2461-2473.	1.1	12
75	Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture. <i>EuroIntervention</i> , 2021, 17, 848-855.	1.4	16
76	Valve-in-Valve Transcatheter Aortic Valve Replacement for the Treatment of Paravalvular Leak Due to Ring Dehiscence. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2746-2746.	1.1	1
77	Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2021, 10, e023129.	1.6	2
78	Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement?. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 522-532.	0.5	28
79	Drug-Eluting Stent Choice in Patients With Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 112-115.	1.1	1
80	Reply. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 139.	1.1	1
81	Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2314-2316.	1.1	0
82	Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta-analysis. <i>ESC Heart Failure</i> , 2020, 7, 3610-3620.	1.4	10
83	Pulmonary Artery Pressure Ventricularization in a Patient With Carcinoid Heart Disease. <i>JACC: Case Reports</i> , 2020, 2, 1200-1204.	0.3	0
84	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. <i>European Heart Journal</i> , 2020, 41, 3743-3749.	1.0	89
85	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	6.3	890
86	Mortality, Stroke, and Hospitalization Associated With Deferred vs Expedited Aortic Valve Replacement in Patients Referred for Symptomatic Severe Aortic Stenosis During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2020, 3, e2020402.	2.8	22
87	A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. <i>American Heart Journal</i> , 2020, 223, 44-47.	1.2	17
88	Impact of Left Ventricular Outflow Tract Calcification on Procedural Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1789-1799.	1.1	66
89	Optimal Fluoroscopic Projections of Coronary Ostia and Bifurcations Defined by Computed Tomographic Coronary Angiography. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2560-2570.	1.1	28
90	Coronary Access After TAVR-in-TAVR as Evaluated by Multidetector Computed Tomography. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2528-2538.	1.1	65

#	ARTICLE	IF	CITATIONS
91	Prosthesisâ€“Patient Mismatch Based on Energy Loss Index After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2584-2586.	1.1	4
92	Reply. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2446-2447.	1.1	1
93	The relationship between baseline diastolic dysfunction and postimplantation invasive hemodynamics with transcatheter aortic valve replacement. <i>Clinical Cardiology</i> , 2020, 43, 1428-1434.	0.7	2
94	Bicuspid Aortic Valve Morphology and Outcomes After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1018-1030.	1.2	143
95	Predilatation and paravalvular leakage risk in TAVR â€“ Authors' reply. <i>Lancet, The</i> , 2020, 396, 600-601.	6.3	0
96	Valvular and Nonvalvular Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2124-2133.	1.1	18
97	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000â€“17. <i>The Lancet Global Health</i> , 2020, 8, e1162-e1185.	2.9	91
98	ACURATE neo: How Is This TAVR Valve Doing to Fit into an Increasingly Crowded Field?. <i>Current Cardiology Reports</i> , 2020, 22, 107.	1.3	10
99	Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1882-1893.	1.2	140
100	Imaging and Patient Selection for Transcatheter Tricuspid Valve Interventions. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 60.	1.1	20
101	Functional Assessment of the Conduction System. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1055-1057.	1.1	1
102	Infective Endocarditis After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3020-3030.	1.2	60
103	Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990â€“2017. <i>Circulation</i> , 2020, 141, 1670-1680.	1.6	206
104	IMPACT OF MITRAL CALCIUM VOLUME ON MITRAL VALVE FUNCTION AND CLINICAL OUTCOMES IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1725.	1.2	0
105	Transcatheter Aortic Valve Replacement in Patients With Multivalvular Heart Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1503-1514.	1.1	38
106	Impact of Predilatation Prior to Transcatheter Aortic Valve Implantation With the Self-Expanding Acurate neo Device (from the Multicenter NEOPRO Registry). <i>American Journal of Cardiology</i> , 2020, 125, 1369-1377.	0.7	15
107	Relationship between Invasive and Echocardiographic Transvalvular Gradients after Transcatheter Aortic Valve Replacement. <i>Cardiology and Therapy</i> , 2020, 9, 201-206.	1.1	2
108	HAS-BLED score and actual bleeding in elderly patients undergoing transcatheter aortic valve implantation. <i>Minerva Medica</i> , 2020, 111, 203-212.	0.3	7

#	ARTICLE	IF	CITATIONS
109	Feasibility and safety of transcaval transcatheter aortic valve implantation: a multicentre European registry. <i>EuroIntervention</i> , 2020, 15, e1319-e1324.	1.4	14
110	Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. <i>EuroIntervention</i> , 2020, 16, 371-379.	1.4	132
111	Long-Term Outcomes After Infective Endocarditis After Transcatheter Aortic Valve Replacement. <i>Circulation</i> , 2020, 142, 1497-1499.	1.6	13
112	Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008024.	1.4	21
113	Prevalence and Evolution of Susceptibility-Weighted Imaging Lesions in Patients With Artificial Heart Valves. <i>Journal of the American Heart Association</i> , 2019, 8, e012814.	1.6	5
114	Case report of simultaneous transcatheter mitral valve-in-valve implantation and percutaneous closure of two paravalvular leaks. <i>European Heart Journal - Case Reports</i> , 2019, 3, ytz123.	0.3	5
115	Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1665-1675.	1.1	23
116	Surgical Transatrial Implantation of Transcatheter Heart Valves in Severe Mitral Annular Calcification. <i>Interventional Cardiology Clinics</i> , 2019, 8, 313-319.	0.2	4
117	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , 2019, 574, 353-358.	13.7	161
118	Percutaneous Mitral Edge-to-Edge Repair: State of the Art and a Glimpse to the Future. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 122.	1.1	14
119	TCT-34 Bioprosthetic Valve Fracture Can Eliminate Pre-Existing Prosthesis-Patient Mismatch. <i>Journal of the American College of Cardiology</i> , 2019, 74, B34.	1.2	1
120	Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. <i>Lancet, The</i> , 2019, 394, 1619-1628.	6.3	189
121	Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. <i>Journal of the American Heart Association</i> , 2019, 8, e013607.	1.6	17
122	Infective Endocarditis Following Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007938.	1.4	36
123	Prognostic Relevance of Left Ventricular Myocardial Performance After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e006612.	1.4	4
124	Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. <i>Lancet, The</i> , 2019, 394, 1243-1253.	6.3	138
125	Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2173-2182.	1.1	60
126	TCT-753 Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prosthesis. <i>Journal of the American College of Cardiology</i> , 2019, 74, B739.	1.2	0

#	ARTICLE	IF	CITATIONS
127	Local Versus General Anesthesia for Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1874-1876.	1.1	3
128	Transcatheter Valve SELECTION in Patients With Right Bundle Branch Block and Impact on Pacemaker Implantations. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1781-1793.	1.1	38
129	Predictors of Left Ventricular Outflow Tract Obstruction After Transcatheter Mitral Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 182-193.	1.1	186
130	TAVR for the Treatment of Degenerated Aortic Bioprostheses. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2656-2659.	1.2	0
131	Incidence and outcome of peri-procedural transcatheter heart valve embolization and migration: the TRAVEL registry (Transcatheter Heart Valve Embolization and Migration). <i>European Heart Journal</i> , 2019, 40, 3156-3165.	1.0	92
132	Edge-to-Edge Mitral Valve Repair With Extended Clip Arms. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1356-1365.	1.1	84
133	Biodegradable-polymer stents versus durable-polymer stents – Authors' reply. <i>Lancet</i> , 2019, 393, 1933.	6.3	1
134	Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. <i>European Heart Journal</i> , 2019, 40, 3143-3153.	1.0	297
135	Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 820-830.	1.1	36
136	Impact of left ventricular function on clinical outcomes among patients with coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1273-1284.	0.8	16
137	Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 433-443.	1.1	59
138	Long-term outcomes with balloon-expandable and self-expandable prostheses in patients undergoing transfemoral transcatheter aortic valve implantation for severe aortic stenosis. <i>International Journal of Cardiology</i> , 2019, 290, 45-51.	0.8	13
139	Valvular Resistance and Bleeding Events Among Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Structural Heart</i> , 2019, 3, 220-228.	0.2	0
140	Impact of valvular resistance on aortic regurgitation after transcatheter aortic valve replacement according to the type of prosthesis. <i>Clinical Research in Cardiology</i> , 2019, 108, 1343-1353.	1.5	3
141	Twenty-Year Trends in the Incidence and Outcome of Cardiogenic Shock in AMIS Plus Registry. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007293.	1.4	72
142	Mechanical complications in patients with ST-segment elevation myocardial infarction: A single centre experience. <i>PLoS ONE</i> , 2019, 14, e0209502.	1.1	21
143	Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 73, 741-754.	1.2	218
144	Patterns of Left Ventricular Geometry and Clinical Outcome After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 383-384.	1.1	0

#	ARTICLE	IF	CITATIONS
145	Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: CardioOncology</i> , 2019, 1, 145-155.	1.7	20
146	Transcatheter aortic valve replacement in patients with concomitant mitral stenosis. <i>European Heart Journal</i> , 2019, 40, 1342-1351.	1.0	29
147	Transcatheter Aortic Valve Replacement in Oncology Patients With Severe Aortic Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 78-86.	1.1	53
148	Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. <i>European Heart Journal</i> , 2019, 40, 441-451.	1.0	271
149	Temporal trends in adoption and outcomes of transcatheter aortic valve implantation: a Swiss TAVI Registry analysis. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 242-251.	1.8	59
150	Percutaneous patent foramen ovale closure during live case demonstrations. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 982-988.	0.7	0
151	Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 577-587.	2.3	85
152	Clinical outcomes in high-risk patients with a severe aortic stenosis: a seven-year follow-up analysis. <i>Swiss Medical Weekly</i> , 2019, 149, w20013.	0.8	1
153	Interventional treatment of mitral valve regurgitation: an alternative to surgery?. <i>Swiss Medical Weekly</i> , 2019, 149, w20023.	0.8	3
154	Optimal fluoroscopic viewing angles of right-sided heart structures in patients with tricuspid regurgitation based on multislice computed tomography. <i>EuroIntervention</i> , 2019, 15, .	1.4	5
155	Can bioprosthetic valve thrombosis be promoted by aortic root morphology? An in vitro study. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 27, 108-115.	0.5	17
156	The Impact of Left Ventricular Diastolic Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 593-601.	1.1	58
157	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	11
158	Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. <i>Open Heart</i> , 2018, 5, e000695.	0.9	36
159	Safety and efficacy of drug-eluting stents combining biodegradable polymers with ultrathin stent platforms. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 2-4.	0.3	1
160	New-onset arrhythmias following transcatheter aortic valve implantation: a systematic review and meta-analysis. <i>Heart</i> , 2018, 104, 1208-1215.	1.2	34
161	Patent foramen ovale closure vs. medical therapy for recurrent stroke prevention: Evolution of treatment effect during follow-up. <i>International Journal of Cardiology</i> , 2018, 255, 29-31.	0.8	7
162	Early Detection of Subclinical Myocardial Damage in Chronic Aortic Regurgitation and Strategies for Timely Treatment of Asymptomatic Patients. <i>Circulation</i> , 2018, 137, 184-196.	1.6	43

#	ARTICLE	IF	CITATIONS
163	Expansion of transcatheter aortic valve implantation: new indications and socio-economic considerations. <i>European Heart Journal</i> , 2018, 39, 2643-2645.	1.0	20
164	Echocardiographic Screening of Rheumatic Heart Disease in American Samoa. <i>Pediatric Cardiology</i> , 2018, 39, 38-44.	0.6	8
165	Circadian dependence of manual thrombus aspiration benefit in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>Clinical Research in Cardiology</i> , 2018, 107, 338-346.	1.5	8
166	Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 398-404.	0.5	36
167	Deciphering the Unknowns of Stroke After Aortic Valve Interventions. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2427-2430.	1.2	0
168	Baseline Troponin T level in stroke and its association with stress cardiomyopathy. <i>PLoS ONE</i> , 2018, 13, e0209764.	1.1	7
169	Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006741.	1.4	13
170	Sheathless Transcaval Transcatheter Aortic Valve Implantation Through an Abdominal Aortic Graft. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1688.e17-1688.e19.	0.8	5
171	Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation. <i>American Journal of Cardiology</i> , 2018, 122, 1028-1035.	0.7	47
172	Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention. <i>American Heart Journal</i> , 2018, 204, 34-42.	1.2	4
173	Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006132.	1.4	38
174	Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. <i>Lancet, The</i> , 2018, 392, 737-746.	6.3	101
175	Fluoroscopic Anatomy of Right-Sided Heart Structures for Transcatheter Interventions. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1614-1625.	1.1	25
176	Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2018, 250, 73-79.	0.8	11
177	A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. <i>EuroIntervention</i> , 2018, 14, 692-699.	1.4	11
178	Current state of alternative access for transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2018, 14, AB40-AB52.	1.4	29
179	Bioprosthetic Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction (BASILICA) during transcatheter aortic valve-in-valve implantation with bioprosthetic valve fracturing via the transcaval access. <i>EuroIntervention</i> , 2018, 14, 884-885.	1.4	4
180	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet, The</i> , 2017, 389, 1025-1034.	6.3	840

#	ARTICLE	IF	CITATIONS
181	Rates and predictors of hospital readmission after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017, 38, 2211-2217.	1.0	54
182	The impact of functional vs degenerative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. <i>American Heart Journal</i> , 2017, 184, 71-80.	1.2	29
183	Type 2 myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 341-347.	0.6	22
184	Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. <i>International Journal of Cardiology</i> , 2017, 243, 150-155.	0.8	23
185	Impact of Patient and Lesion Complexity on Long-Term Outcomes Following Coronary Revascularization With New-Generation Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2017, 119, 501-507.	0.7	10
186	Dual antiplatelet therapy for secondary prevention of coronary artery disease. <i>Open Heart</i> , 2017, 4, e000651.	0.9	49
187	Strategies for Paravalvular Prosthetic Leak Closure. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1970-1972.	1.1	7
188	Transcatheter Aortic Valve Replacement in Patients With Chronic Lung Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2294-2296.	1.1	1
189	Transcatheter Mitral Valve Replacement for Degenerated Bioprosthetic Valves and Failed Annuloplasty Rings. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1121-1131.	1.2	183
190	Evolving Indications for Transcatheter Aortic Valve Interventions. <i>Current Cardiology Reports</i> , 2017, 19, 107.	1.3	14
191	Orsiro cobalt-chromium sirolimus-eluting stent: present and future perspectives. <i>Expert Review of Medical Devices</i> , 2017, 14, 773-788.	1.4	29
192	Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1436-1446.	1.1	99
193	Predicting Mortality After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	32
194	Coronary artery disease and myocardial revascularization in patients undergoing transcatheter aortic valve replacement. <i>Journal of Thoracic Disease</i> , 2017, 9, 4219-4221.	0.6	1
195	Prognostic impact of invasive haemodynamic measurements in combination with clinical and echocardiographic characteristics on two-year clinical outcomes of patients undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2017, 12, e2186-e2193.	1.4	10
196	Atrial Fibrillation on Vitamin K Antagonist Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. , 2017, , 1-18.		0
197	Preprocedural High-Sensitivity Cardiac Troponin T and Clinical Outcomes in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	18
198	Predictors of Early (1-Week) Outcomes Following Left Atrial Appendage Closure With Amplatzer Devices. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1374-1383.	1.1	38

#	ARTICLE	IF	CITATIONS
199	Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016, 37, 3503-3512.	1.0	275
200	Repositionable Versus Balloon-Expandable Devices for Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	25
201	Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 981-983.	1.1	7
202	Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial. <i>Journal of the American Heart Association</i> , 2016, 5, e003255.	1.6	50
203	Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. <i>European Heart Journal</i> , 2016, 37, 3386-3395.	1.0	80
204	Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1083.	3.8	241
205	Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1473-1483.	1.1	24
206	Prevalence of Subclinical Rheumatic Heart Disease in Eastern Nepal. <i>JAMA Cardiology</i> , 2016, 1, 89.	3.0	53
207	Newer-Generation Devices for Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 373-375.	1.1	6
208	Transcatheter Aortic Valve Replacement for the Treatment of Pure Native Aortic Valve Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2308-2317.	1.1	102
209	External validity of the "all-comers" design: insights from the BIOSCIENCE trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 744-754.	1.5	11
210	Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016, 118, 345-352.	0.7	16
211	Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. <i>Circulation</i> , 2016, 133, 650-660.	1.6	260
212	Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. <i>European Heart Journal</i> , 2016, 37, 229-240.	1.0	197
213	CardioPulse ArticlesValvular interventions from the European perspectiveTranscatheter aortic valve replacementChristopher Paul Cannon MDActive surveillance for latent rheumatic heart disease in NepalA new European Society of Cardiology research database: Atlas of CardiologyPeople's corner: promotionProfessor Stephan Windecker. <i>European Heart Journal</i> . 2016. 37. 796-802.	1.0	0
214	Short-term catheter based treatment of aortic regurgitation by Edwards' Sapien 3 valve-in-valve implantation because of a poorly placed Medtronic CoreValve. <i>International Journal of Cardiology</i> , 2016, 207, 120-121.	0.8	1
215	Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003255.	1.4	88
216	Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 175, 56-65.	1.2	61

#	ARTICLE	IF	CITATIONS
217	Post-Procedure Troponin Elevation and Clinical Outcomes Following Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	41
218	Effect of resting heart rate on two-year clinical outcomes of high-risk patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2016, 12, 490-498.	1.4	4
219	Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial. <i>EuroIntervention</i> , 2016, 12, e595-e604.	1.4	11
220	External validity of a contemporaneous primary percutaneous coronary intervention trial in patients with acute ST-elevation myocardial infarction: insights from a single-centre investigation. <i>EuroIntervention</i> , 2016, 12, 1135-1143.	1.4	4
221	Bilateral, reversible coronary obstruction during aortic valve-in-valve implantation of a repositionable valve system. <i>EuroIntervention</i> , 2016, 12, 1195-1195.	1.4	2
222	Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study. <i>EuroIntervention</i> , 2016, 12, 482-489.	1.4	25
223	Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. <i>EuroIntervention</i> , 2016, 12, e1343-e1354.	1.4	27
224	Screening for Rheumatic Heart Disease among Peruvian Children: A Two-Stage Sampling Observational Study. <i>PLoS ONE</i> , 2015, 10, e0133004.	1.1	13
225	Age- and Gender-related Disparities in Primary Percutaneous Coronary Interventions for Acute ST-segment elevation Myocardial Infarction. <i>PLoS ONE</i> , 2015, 10, e0137047.	1.1	26
226	Clinical Impact of Gastrointestinal Bleeding in Patients Undergoing Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	75
227	Comparing the incomparable: studies of echocardiographic rheumatic heart disease prevalence – Authors' reply. <i>The Lancet Global Health</i> , 2015, 3, e193.	2.9	0
228	Once normal coronary arteries, always normal coronary arteries?. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 406-407.	0.7	0
229	Impact of Mitral Regurgitation on Clinical Outcomes of Patients With Low-Ejection Fraction, Low-Gradient Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001895.	1.4	25
230	Clinical Outcomes According to Diabetic Status in Patients Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	29
231	Aspiration Thrombectomy for Treatment of ST-segment Elevation Myocardial Infarction: a Meta-analysis of 26 Randomized Trials in 11 943 Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 746-752.	0.4	8
232	Clinical Outcomes and Revascularization Strategies in Patients With Low-Flow, Low-Gradient Severe Aortic Valve Stenosis According to the Assigned Treatment Modality. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 704-717.	1.1	39
233	Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2015, 104, 656-665.	1.5	66
234	Republished: Antiplatelet therapy for secondary prevention of coronary artery disease. <i>Postgraduate Medical Journal</i> , 2015, 91, 284-290.	0.9	1

#	ARTICLE	IF	CITATIONS
235	Validation of the Valve Academic Research Consortium Bleeding Definition in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2015, 4, e002135.	1.6	23
236	Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002358.	1.4	107
237	Response To Letter Regarding Article, "Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation: Insights From the New Proposed Pulmonary Hypertension Classification". <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e003064.	1.4	3
238	Effect of B-type Natriuretic Peptides on Long-Term Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2015, 116, 1560-1565.	0.7	47
239	Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1335-1338.	1.2	6
240	TCT-335 Diagnostic concordance of intravascular ultrasound imaging compared to fractional flow reserve for the severity assessment of coronary lesions: A bivariate meta-analysis. <i>Journal of the American College of Cardiology</i> , 2015, 66, B135.	1.2	0
241	Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1657-1666.	1.1	38
242	Long-term outcome of elderly patients with severe aortic stenosis as a function of treatment modality. <i>Heart</i> , 2015, 101, 30-36.	1.2	26
243	Five-year results of a randomised comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularisation. <i>EuroIntervention</i> , 2015, 10, 1284-1287.	1.4	7
244	Foreign Body Retrieval in Vascular System. , 2015, , 4549-4563.		0
245	Will this trial change my practice? ABSORB II trial (a bioresorbable vascular scaffold versus) Tj ETQq1 1 0.784314 rgBJ /Overlock 10 Tt 5	1.4	1
246	Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents. <i>The Lancet Global Health</i> , 2014, 2, e717-e726.	2.9	156
247	Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014, 35, 2530-2540.	1.0	140
248	Pregnancy complicated by heart disease in Nepal. <i>Heart Asia</i> , 2014, 6, 26-29.	1.1	11
249	Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: An optical coherence tomography study. <i>International Journal of Cardiology</i> , 2014, 173, 259-267.	0.8	44
250	Acute Carotid T Occlusion in a Young Patient. <i>Stroke</i> , 2014, 45, e125-7.	1.0	2
251	Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. <i>Lancet, The</i> , 2014, 384, 2111-2122.	6.3	224
252	TCT-731 REASONS FOR HOSPITAL READMISSION WITHIN ONE YEAR AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION. <i>Journal of the American College of Cardiology</i> , 2014, 64, B214.	1.2	0

#	ARTICLE	IF	CITATIONS
253	Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2014, 114, 1447-1455.	0.7	82
254	Predictors of Permanent Pacemaker Implantation in Patients With Severe Aortic Stenosis Undergoing TAVR. <i>Journal of the American College of Cardiology</i> , 2014, 64, 129-140.	1.2	536
255	Antiplatelet therapy for secondary prevention of coronary artery disease. <i>Heart</i> , 2014, 100, 1750-1756.	1.2	33
256	Drug-eluting stent technology: progress beyond the polymer. <i>European Heart Journal</i> , 2014, 35, 1991-1995.	1.0	10
257	O144 Pregnancy Complicated by Heart Disease in Nepal. , 2014, 9, e39-e40.		2
258	Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: Rationale and design of the BIOSCIENCE trial. <i>American Heart Journal</i> , 2014, 168, 256-261.	1.2	16
259	Feasibility and outcomes of combined transcatheter aortic valve replacement with other structural heart interventions in a single session: a matched cohort study. <i>Open Heart</i> , 2014, 1, e000014.	0.9	10
260	The Impact of Renal Impairment on Long-Term Safety and Effectiveness of Drug-Eluting Stents. <i>PLoS ONE</i> , 2014, 9, e106450.	1.1	10
261	Additive Effect of Anemia and Renal Impairment on Long-Term Outcome after Percutaneous Coronary Intervention. <i>PLoS ONE</i> , 2014, 9, e114846.	1.1	13
262	Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents. <i>EuroIntervention</i> , 2014, 9, 1076-1084.	1.4	33
263	Foreign Body Retrieval in Vascular System. , 2014, , 1-15.		0
264	Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 456-462.	1.0	64
265	TCT-727 Impact Of Coronary Artery Disease Severity Assessed by SYNTAX-Score On Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2013, 62, B222.	1.2	0
266	TCT-712 Clinical Outcomes of Patients With Low Flow, Low Gradient Severe Aortic Stenosis According To Treatment Modality. <i>Journal of the American College of Cardiology</i> , 2013, 62, B217.	1.2	0
267	Clinical outcomes of patients with low-flow, low-gradient, severe aortic stenosis and either preserved or reduced ejection fraction undergoing transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2013, 34, 3437-3450.	1.0	102
268	Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2013, 34, 1894-1905.	1.0	140
269	Atrial Fibrillation and Aortic Stenosis. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 77-84.	1.4	108
270	Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents. <i>EuroIntervention</i> , 2013, 8, 1061-1071.	1.4	43

#	ARTICLE	IF	CITATIONS
271	Percutaneous coronary intervention for acute coronary syndromes in eastern Nepal: a preliminary report. <i>Swiss Medical Weekly</i> , 2013, 143, w13737.	0.8	3
272	Death by patent foramen ovale in a soccer player. <i>Journal of Invasive Cardiology</i> , 2013, 25, 162-4.	0.4	9
273	Emergency transcatheter aortic valve implantation for decompensated aortic stenosis. <i>Journal of Invasive Cardiology</i> , 2013, 25, 247-9.	0.4	2
274	Letter by Pilgrim Regarding Article, "Echocardiography Screening for Rheumatic Heart Disease in Ugandan Schoolchildren". <i>Circulation</i> , 2012, 126, e475; author reply e478-9.	1.6	0
275	Rheumatic heart disease: pilot study for a population-based evaluation of prevalence and cardiovascular outcomes among schoolchildren in Nepal: Table A1. <i>BMJ Open</i> , 2012, 2, e001616.	0.8	6
276	Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 977-987.	1.0	134
277	The Impact of Anemia on Long-Term Clinical Outcome in Patients Undergoing Revascularization With the Unrestricted Use of Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 202-210.	1.4	61
278	Predictors of Clinical Outcomes in Patients With Severe Aortic Stenosis Undergoing TAVI. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 856-861.	1.4	46
279	Rheumatic heart disease revisited. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 755-759.	0.6	17
280	Protocol for a population-based study of rheumatic heart disease prevalence and cardiovascular outcomes among schoolchildren in Nepal. <i>BMJ Open</i> , 2012, 2, e001320.	0.8	8
281	Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. <i>American Heart Journal</i> , 2012, 163, 876-886.e2.	1.2	26
282	Assessment of coronary artery disease by post-mortem cardiac MR. <i>European Journal of Radiology</i> , 2012, 81, 2208-2214.	1.2	28
283	Impact of Permanent Pacemaker Implantation on Clinical Outcome Among Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 493-501.	1.2	195
284	TCT-605 Impact Of Stent Overlap On Long-Term Clinical Outcomes In Patients Treated With Newer-Generation Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2012, 60, B175.	1.2	0
285	Long-Term Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 145-154.	1.1	15
286	Impact of Sex on Clinical and Angiographic Outcomes Among Patients Undergoing Revascularization With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 301-310.	1.1	64
287	Percutaneous Management of Vascular Complications in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 515-524.	1.1	69
288	Long-Term Vascular Healing in Response to Sirolimus- and Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 946-957.	1.1	55

#	ARTICLE	IF	CITATIONS
289	Percutaneous left atrial appendage closure. <i>European Geriatric Medicine</i> , 2012, 3, 308-311.	1.2	7
290	Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes. <i>EuroIntervention</i> , 2012, 8, 62-70.	1.4	100
291	Improvement of physical and mental health after transfemoral transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2012, 8, 437-443.	1.4	18
292	Clinical Outcomes of Patients With Severe Aortic Stenosis at Increased Surgical Risk According to Treatment Modality. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2151-2162.	1.2	150
293	2-Year Clinical Follow-Up From the Randomized Comparison of Biolimus-Eluting Stents With Biodegradable Polymer and Sirolimus-Eluting Stents With Durable Polymer in Routine Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 887-895.	1.1	32
294	Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes. <i>American Heart Journal</i> , 2011, 161, 1114-1124.	1.2	115
295	Clinical Outcome of High-Risk Patients with Severe Aortic Stenosis and Reduced Left Ventricular Ejection Fraction Undergoing Medical Treatment or TAVI. <i>PLoS ONE</i> , 2011, 6, e27556.	1.1	47
296	Impact of Body Mass Index on the Five-Year Outcome of Patients Having Percutaneous Coronary Interventions With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2011, 108, 195-201.	0.7	37
297	Transcatheter Aortic Valve Implantation or Surgical Aortic Valve Replacement as Redo Procedure After Prior Coronary Artery Bypass Grafting. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1324-1331.	0.7	47
298	Comparison of Titanium-Nitride-Oxide-Coated Stents With Zotarolimus-Eluting Stents for Coronary Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 672-682.	1.1	25
299	Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2011, 7, 541-548.	1.4	156
300	Presentation and outcome of patients with acute coronary syndromes in eastern Nepal. <i>Swiss Medical Weekly</i> , 2011, 141, w13174.	0.8	2
301	Comparing outcomes between surgical aortic valve replacement and transcatheter aortic valve implantation. <i>Interventional Cardiology</i> , 2010, 2, 681-694.	0.0	1
302	Incidence and Predictors of Atrioventricular Conduction Impairment After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2010, 106, 1473-1480.	0.7	158
303	Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving System-A Bern-Rotterdam Study. <i>American Heart Journal</i> , 2010, 159, 323-329.	1.2	149
304	Primary Percutaneous Coronary Intervention. , 2010, , 78-90.		0
305	Aorto-right ventricular fistula after transfemoral aortic valve implantation. <i>Journal of Invasive Cardiology</i> , 2010, 22, E30-1.	0.4	14
306	Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: A systematic review. <i>International Journal of Cardiology</i> , 2008, 124, 283-292.	0.8	444

#	ARTICLE	IF	CITATIONS
307	Diagnostic performance of cardiac magnetic resonance segmental myocardial strain for detecting microvascular obstruction and late gadolinium enhancement in patients presenting after a ST-elevation myocardial infarction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	8